

Anna Vanazzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3821223/publications.pdf>

Version: 2024-02-01

37
papers

279
citations

933447

10
h-index

940533

16
g-index

37
all docs

37
docs citations

37
times ranked

542
citing authors

#	ARTICLE	IF	CITATIONS
1	How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2022, , 1-4.	1.3	3
2	The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade. <i>Blood Advances</i> , 2022, 6, 4634-4644.	5.2	4
3	Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial. <i>Blood Advances</i> , 2020, 4, 5951-5957.	5.2	9
4	Treatment of very high-risk classical Hodgkin Lymphoma: cases' selection from real life and critical review of the literature. <i>Acta Biomedica</i> , 2020, 91, 13-22.	0.3	24
5	Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. <i>Blood</i> , 2019, 134, 353-362.	1.4	45
6	Lymphoma Occurring during Pregnancy: Obstetric Outcome and Overall Survival in a Series of 19 Patients. <i>Blood</i> , 2019, 134, 5289-5289.	1.4	0
7	Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): The Experience at European Institute of Oncology (EIO). <i>Blood</i> , 2019, 134, 5283-5283.	1.4	0
8	Rituximab Maintenance Treatment for a Maximum of 5 Years in Follicular Lymphoma: Final Results of the Randomized Phase III Trial SAKK 35/03. <i>Blood</i> , 2018, 132, 1601-1601.	1.4	1
9	Integration of Nanostring Profiling and Functional Characterization of Oxidative and Replicative Stress Biomarkers Identifies Poor Prognosis MYC/BCL-2 Positive Diffuse Large B-Cell Lymphoma Subsets, Providing Opportunities for Precision Therapies. <i>Blood</i> , 2018, 132, 676-676.	1.4	1
10	Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. <i>Oncotarget</i> , 2018, 9, 23443-23450.	1.8	12
11	Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma. <i>Haematologica</i> , 2017, 102, 1931-1935.	3.5	11
12	Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma. <i>Oncotarget</i> , 2017, 8, 91703-91710.	1.8	21
13	Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03. <i>Journal of Clinical Oncology</i> , 2016, 34, 495-500.	1.6	49
14	Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10. <i>Blood</i> , 2016, 128, 1099-1099.	1.4	7
15	Prognostic Value of End of Treatment FDG-PET Scan in T-Cell Lymphoma, a 20-Year Single Institution Study. <i>Blood</i> , 2016, 128, 3003-3003.	1.4	1
16	Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Hodgkin's Lymphoma. <i>Blood</i> , 2016, 128, 4161-4161.	1.4	0
17	Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2016, 128, 3007-3007.	1.4	0
18	Chronic lymphocytic leukaemia during pregnancy: management and thoughts. <i>Ecancermedicalsecience</i> , 2015, 9, 592.	1.1	3

#	ARTICLE	IF	CITATIONS
19	Chlorambucil+rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study. Hematological Oncology, 2015, 33, 129-135.	1.7	11
20	Efficacy of ⁹⁰ Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma. Hematological Oncology, 2014, 32, 10-15.	1.7	24
21	Rituximab Maintenance Treatment For a Maximum Of 5 Years In Follicular Lymphoma: Results Of The Randomized Phase III Trial SAKK 35/03. Blood, 2013, 122, 508-508.	1.4	6
22	The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia and Second Malignancy Following Yttrium-90 Ibritumomab Tiuxetan: 10-Year Single-Institution Experience of 138 Consecutive Patients. Blood, 2012, 120, 4876-4876.	1.4	2
23	Efficacy of ⁹⁰ yttrium-ibritumomab Tiuxetan in Extranodal Marginal-Zone Lymphoma,. Blood, 2011, 118, 3713-3713.	1.4	0
24	A New Induction Combination Therapy (ThalDoDex) for Multiple Myeloma. Preliminary Results of a Phase II Study. Blood, 2010, 116, 5030-5030.	1.4	0
25	Rituximab Plus Chlorambucil Compared with Chlorambucil and Prednisone In Patients with Untreated Follicular Lymphoma. Blood, 2010, 116, 3956-3956.	1.4	0
26	Rituximab and Chlorambucil as Front-Line Treatment in Untreated Follicular Lymphoma: a Combination with a Durable Response and Low Toxicity Profile.. Blood, 2009, 114, 3754-3754.	1.4	0
27	⁹⁰ y-ibritumomab Tiuxetan or Purine Analogues Severely Affect Peripheral Blood Stem Cell Mobilization: An Analysis On 248 Patients.. Blood, 2009, 114, 3210-3210.	1.4	0
28	Red Marrow Dosimetry and Stem Cell Reinfusion in High Dose ⁹⁰ Y - Ibritumomab Tiuxetan.. Blood, 2008, 112, 2187-2187.	1.4	2
29	Efficacy of ⁹⁰ Y - Ibritumomab Tiuxetan in Relapsed or Refractory Primary Gastric Non Hodgkin Lymphoma. Blood, 2008, 112, 3063-3063.	1.4	1
30	Evolving First-Line Treatments -from Chemotherapy to Immunotherapy Alone- in 143 Consecutive Follicular Lymphoma Patients Treated in the Last 14 Years at the European Institute of Oncology, Milano. Blood, 2008, 112, 5016-5016.	1.4	5
31	High Dose ⁹⁰ Yttrium Ibritumomab Tiuxetan with PBSC Support in Refractory-Resistant NHL Patients.. Blood, 2007, 110, 1890-1890.	1.4	3
32	Efficacy of ⁹⁰ Y-ibritumomab Tiuxetan in Marginal-Zone Lymphoma (MZL).. Blood, 2007, 110, 4499-4499.	1.4	4
33	High Dose ⁹⁰ Yttrium Ibritumomab Tiuxetan (Zevalin) with PBSC Support in Refractory-Resistant NHL Patients: A Phase I/II Study.. Blood, 2006, 108, 2720-2720.	1.4	11
34	Efficacy of ⁹⁰ Y-ibritumomab Tiuxetan (Zevalin) in Refractory or Relapsed MALT Gastric Non Hodgkin's Lymphoma.. Blood, 2006, 108, 2771-2771.	1.4	2
35	Tissue Microarray (TMA) Study in DLBC Lymphomas (DLBCL): Could the Extranodal Origin Affect the Prognostic Impact of the Analysis?.. Blood, 2006, 108, 2037-2037.	1.4	5
36	High Dose Zevalin (⁹⁰ Yttrium Ibritumomab Tiuxetan) Treatment with PBSC Support in Refractory-Resistant NHL Patients: Preliminary Results of a Phase I/II Study.. Blood, 2005, 106, 488-488.	1.4	12

#	ARTICLE	IF	CITATIONS
37	Prognostic Value of BCL2 Determination in Follicular NHL Patients Treated with Alkylating Containing Regimen Alone or in Combination with Rituximab.. Blood, 2004, 104, 4629-4629.	1.4	0